Enhanced	O
gastric	O
stability	O
of	O
esomeprazole	B:C0937846
by	O
molecular	O
interaction	I:C1167622
and	O
modulation	O
of	O
microenvironmental	O
pH	O
with	O
alkalizers	O
in	O
solid	O
dispersion	I:C3859614
.	O

Enhanced	O
gastric	O
stability	O
of	O
esomeprazole	O
by	O
molecular	B:C1167622
interaction	I:C1167622
and	O
modulation	O
of	O
microenvironmental	O
pH	O
with	O
alkalizers	O
in	O
solid	O
dispersion	I:C3859614
.	O

Enhanced	O
gastric	O
stability	O
of	O
esomeprazole	O
by	O
molecular	O
interaction	I:C1167622
and	O
modulation	O
of	O
microenvironmental	O
pH	O
with	O
alkalizers	B:C0304463
in	O
solid	O
dispersion	I:C3859614
.	O

Enhanced	O
gastric	O
stability	O
of	O
esomeprazole	O
by	O
molecular	O
interaction	I:C1167622
and	O
modulation	O
of	O
microenvironmental	O
pH	O
with	O
alkalizers	O
in	O
solid	B:C3859614
dispersion	I:C3859614
.	O

Due	O
to	O
the	O
instability	B:C0443343
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	O
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	O
fluid	I:C2828094
,	O
enteric	O
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	I:C0087111
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	O
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	O
fluid	I:C2828094
,	O
enteric	O
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	I:C0087111
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	O
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	O
fluid	I:C2828094
,	O
enteric	O
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	I:C0087111
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	B:C0358591
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	O
fluid	I:C2828094
,	O
enteric	O
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	I:C0087111
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	O
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	B:C2828094
fluid	I:C2828094
,	O
enteric	O
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	I:C0087111
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	O
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	O
fluid	I:C2828094
,	O
enteric	B:C0039226
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	I:C0087111
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
(	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
)	O
,	O
a	O
proton	O
pump	I:C0358591
inhibitor	I:C0358591
,	O
in	O
gastric	O
fluid	I:C2828094
,	O
enteric	O
-	I:C0039226
coated	I:C0039226
dosage	I:C0039226
form	O
is	O
commonly	O
used	O
for	O
therapeutic	B:C0087111
application	I:C0087111
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
prepared	O
new	O
gastric	O
fluid	I:C2828094
resistant	O
solid	O
dispersions	I:C3859614
(	O
solid	O
dispersions	I:C3859614
)	O
containing	O
alkalizers	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
new	O
gastric	B:C2828094
fluid	I:C2828094
resistant	O
solid	O
dispersions	I:C3859614
(	O
solid	O
dispersions	I:C3859614
)	O
containing	O
alkalizers	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
new	O
gastric	O
fluid	I:C2828094
resistant	O
solid	B:C3859614
dispersions	I:C3859614
(	O
solid	O
dispersions	I:C3859614
)	O
containing	O
alkalizers	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
new	O
gastric	O
fluid	I:C2828094
resistant	O
solid	O
dispersions	I:C3859614
(	O
solid	B:C3859614
dispersions	I:C3859614
)	O
containing	O
alkalizers	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
new	O
gastric	O
fluid	I:C2828094
resistant	O
solid	O
dispersions	I:C3859614
(	O
solid	O
dispersions	I:C3859614
)	O
containing	O
alkalizers	B:C0304463
.	O

Then	O
,	O
new	O
mechanistic	O
evidence	O
regarding	O
the	O
effects	O
of	O
pharmaceutical	B:C0013227
alkalizers	O
on	O
the	O
aqueous	O
stability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
was	O
investigated	O
.	O

Then	O
,	O
new	O
mechanistic	O
evidence	O
regarding	O
the	O
effects	O
of	O
pharmaceutical	O
alkalizers	B:C0304463
on	O
the	O
aqueous	O
stability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
was	O
investigated	O
.	O

Then	O
,	O
new	O
mechanistic	O
evidence	O
regarding	O
the	O
effects	O
of	O
pharmaceutical	O
alkalizers	O
on	O
the	O
aqueous	O
stability	O
of	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
was	O
investigated	O
.	O

Then	O
,	O
new	O
mechanistic	O
evidence	O
regarding	O
the	O
effects	O
of	O
pharmaceutical	O
alkalizers	O
on	O
the	O
aqueous	O
stability	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	B:C2828094
fluid	I:C2828094
was	O
investigated	O
.	O

The	O
alkalizer	B:C0304463
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	B:C3859614
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	B:C0063242
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	B:C0063242
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	B:C0304463
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	B:C0001962
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	O
drying	I:C3827958
.	O

The	O
alkalizer	O
-	O
loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
hydroxypropyl	O
methylcellulose	I:C0063242
(	O
hydroxypropyl	O
methylcellulose	I:C0063242
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
followed	O
by	O
spray	B:C3827958
drying	I:C3827958
.	O

Nine	O
different	O
alkalizer	B:C0304463
s	O
were	O
assessed	O
for	O
in	O
vitro	O
stability	O
in	O
two	O
media	O
,	O
simulated	O
gastric	O
fluid	I:C2828094
(	O
pH	O
1.2	O
buffer	O
)	O
and	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
6.8	O
buffer	O
)	O
.	O

Nine	O
different	O
alkalizer	O
s	O
were	O
assessed	O
for	O
in	O
vitro	O
stability	O
in	O
two	O
media	O
,	O
simulated	O
gastric	B:C2828094
fluid	I:C2828094
(	O
pH	O
1.2	O
buffer	O
)	O
and	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
6.8	O
buffer	O
)	O
.	O

Nine	O
different	O
alkalizer	O
s	O
were	O
assessed	O
for	O
in	O
vitro	O
stability	O
in	O
two	O
media	O
,	O
simulated	O
gastric	O
fluid	I:C2828094
(	O
pH	O
1.2	O
buffer	B:C0006353
)	O
and	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
6.8	O
buffer	O
)	O
.	O

Nine	O
different	O
alkalizer	O
s	O
were	O
assessed	O
for	O
in	O
vitro	O
stability	O
in	O
two	O
media	O
,	O
simulated	O
gastric	O
fluid	I:C2828094
(	O
pH	O
1.2	O
buffer	O
)	O
and	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
6.8	O
buffer	B:C0006353
)	O
.	O

The	O
microenvironmental	O
pH	O
(	O
pHM	O
)	O
was	O
measured	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
alkalizer	B:C0304463
on	O
the	O
pHM	O
of	O
solid	O
dispersions	I:C3859614
.	O

The	O
microenvironmental	O
pH	O
(	O
pHM	O
)	O
was	O
measured	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
alkalizer	O
on	O
the	O
pHM	O
of	O
solid	B:C3859614
dispersions	I:C3859614
.	O

Drug	O
crystallinity	B:C0444626
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	B:C3859614
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	B:C0043301
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	B:C0043301
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	B:C0026020
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
solid	O
dispersions	I:C3859614
were	O
also	O
examined	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
,	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
(	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
)	O
,	O
and	O
scanning	O
electron	I:C0026020
microscopy	I:C0026020
(	O
scanning	B:C0026020
electron	I:C0026020
microscopy	I:C0026020
)	O
.	O

The	O
interactions	O
among	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
the	O
polymer	O
,	O
and	O
the	O
alkalizer	O
were	O
elucidated	O
by	O
Fourier	O
transform	I:C0206055
infrared	I:C0206055
(	I:C0206055
FTIR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
.	O

The	O
interactions	O
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
the	O
polymer	B:C0063242
,	O
and	O
the	O
alkalizer	O
were	O
elucidated	O
by	O
Fourier	O
transform	I:C0206055
infrared	I:C0206055
(	I:C0206055
FTIR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
.	O

The	O
interactions	O
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
the	O
polymer	O
,	O
and	O
the	O
alkalizer	B:C0304463
were	O
elucidated	O
by	O
Fourier	O
transform	I:C0206055
infrared	I:C0206055
(	I:C0206055
FTIR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
.	O

The	O
interactions	O
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
the	O
polymer	O
,	O
and	O
the	O
alkalizer	O
were	O
elucidated	O
by	O
Fourier	B:C0206055
transform	I:C0206055
infrared	I:C0206055
(	I:C0206055
FTIR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
.	O

The	O
in	B:C1515655
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	O
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	B:C2603343
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	O
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	B:C0304463
-	O
containing	O
SD	O
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	B:C3859614
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	O
and	O
the	O
enteric	B:C0039226
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	O
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	B:C0013227
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	O
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	B:C0939400
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	I:C0324306
.	O

The	O
in	O
vivo	I:C1515655
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-	O
containing	O
SD	O
and	O
the	O
enteric	O
-	I:C0039226
coated	I:C0039226
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	B:C0324306
dogs	I:C0324306
.	O

Among	O
alkalizer	B:C0304463
s	O
,	O
MgO	O
loaded	O
in	O
solid	O
dispersions	I:C3859614
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	B:C0024477
loaded	O
in	O
solid	O
dispersions	I:C3859614
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	O
loaded	O
in	O
solid	B:C3859614
dispersions	I:C3859614
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	O
loaded	O
in	O
solid	O
dispersions	I:C3859614
proved	O
to	O
be	O
the	O
best	O
alkalizer	B:C0304463
to	O
stabilize	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	O
loaded	O
in	O
solid	O
dispersions	I:C3859614
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	O
fluid	I:C2828094
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	O
loaded	O
in	O
solid	O
dispersions	I:C3859614
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
in	O
simulated	O
gastric	B:C2828094
fluid	I:C2828094
.	O

pHM	O
values	O
of	O
the	O
alkalizer	B:C0304463
-	O
containing	O
solid	O
dispersions	I:C3859614
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SD	O
without	O
alkalizer	O
.	O

pHM	O
values	O
of	O
the	O
alkalizer	O
-	O
containing	O
solid	B:C3859614
dispersions	I:C3859614
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SD	O
without	O
alkalizer	O
.	O

pHM	O
values	O
of	O
the	O
alkalizer	O
-	O
containing	O
solid	O
dispersions	I:C3859614
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SD	B:C3859614
without	O
alkalizer	O
.	O

pHM	O
values	O
of	O
the	O
alkalizer	O
-	O
containing	O
solid	O
dispersions	I:C3859614
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SD	O
without	O
alkalizer	B:C0304463
.	O

The	O
pHM	O
values	O
decreased	O
in	O
the	O
following	O
order	O
:	O
MgO	B:C0024477
,	O
Na2CO3	O
,	O
Ca(	O
OH	I:C0006701
)	I:C0006701
2	I:C0006701
,	O
and	O
no	O
alkalizer	O
.	O

The	O
pHM	O
values	O
decreased	O
in	O
the	O
following	O
order	O
:	O
MgO	O
,	O
Na2CO3	B:C0074732
,	O
Ca(	O
OH	I:C0006701
)	I:C0006701
2	I:C0006701
,	O
and	O
no	O
alkalizer	O
.	O

The	O
pHM	O
values	O
decreased	O
in	O
the	O
following	O
order	O
:	O
MgO	O
,	O
Na2CO3	O
,	O
Ca(	B:C0006701
OH	I:C0006701
)	I:C0006701
2	I:C0006701
,	O
and	O
no	O
alkalizer	O
.	O

The	O
pHM	O
values	O
decreased	O
in	O
the	O
following	O
order	O
:	O
MgO	O
,	O
Na2CO3	O
,	O
Ca(	O
OH	I:C0006701
)	I:C0006701
2	I:C0006701
,	O
and	O
no	O
alkalizer	B:C0304463
.	O

differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
and	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	O
of	O
the	O
solid	O
dispersions	I:C3859614
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

differential	O
scanning	I:C0006780
calorimetry	I:C0006780
and	O
powder	B:C0043301
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	O
of	O
the	O
solid	O
dispersions	I:C3859614
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

differential	O
scanning	I:C0006780
calorimetry	I:C0006780
and	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	B:C0013227
crystallinity	O
of	O
the	O
solid	O
dispersions	I:C3859614
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

differential	O
scanning	I:C0006780
calorimetry	I:C0006780
and	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	B:C0444626
of	O
the	O
solid	O
dispersions	I:C3859614
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

differential	O
scanning	I:C0006780
calorimetry	I:C0006780
and	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	O
of	O
the	O
solid	B:C3859614
dispersions	I:C3859614
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

differential	O
scanning	I:C0006780
calorimetry	I:C0006780
and	O
powder	O
X	I:C0043301
-	I:C0043301
ray	I:C0043301
diffraction	I:C0043301
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	O
of	O
the	O
solid	O
dispersions	I:C3859614
from	O
crystalline	B:C0444626
to	O
amorphous	O
form	O
.	O

scanning	B:C0026020
electron	I:C0026020
microscopy	I:C0026020
data	O
showed	O
a	O
relatively	O
spherical	O
shape	I:C0332501
of	O
the	O
MgO	O
-	O
loaded	O
SD	O
compared	O
to	O
the	O
less	O
-	O
defined	O
shape	O
of	O
pure	O
drug	O
.	O

scanning	O
electron	I:C0026020
microscopy	I:C0026020
data	O
showed	O
a	O
relatively	O
spherical	B:C0332501
shape	I:C0332501
of	O
the	O
MgO	O
-	O
loaded	O
SD	O
compared	O
to	O
the	O
less	O
-	O
defined	O
shape	O
of	O
pure	O
drug	O
.	O

scanning	O
electron	I:C0026020
microscopy	I:C0026020
data	O
showed	O
a	O
relatively	O
spherical	O
shape	I:C0332501
of	O
the	O
MgO	B:C0024477
-	O
loaded	O
SD	O
compared	O
to	O
the	O
less	O
-	O
defined	O
shape	O
of	O
pure	O
drug	O
.	O

scanning	O
electron	I:C0026020
microscopy	I:C0026020
data	O
showed	O
a	O
relatively	O
spherical	O
shape	I:C0332501
of	O
the	O
MgO	O
-	O
loaded	O
SD	B:C3859614
compared	O
to	O
the	O
less	O
-	O
defined	O
shape	O
of	O
pure	O
drug	O
.	O

scanning	O
electron	I:C0026020
microscopy	I:C0026020
data	O
showed	O
a	O
relatively	O
spherical	O
shape	I:C0332501
of	O
the	O
MgO	O
-	O
loaded	O
SD	O
compared	O
to	O
the	O
less	O
-	O
defined	O
shape	B:C0332479
of	O
pure	O
drug	O
.	O

scanning	O
electron	I:C0026020
microscopy	I:C0026020
data	O
showed	O
a	O
relatively	O
spherical	O
shape	I:C0332501
of	O
the	O
MgO	O
-	O
loaded	O
SD	O
compared	O
to	O
the	O
less	O
-	O
defined	O
shape	O
of	O
pure	O
drug	B:C0013227
.	O

Fourier	B:C0206055
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	O
interaction	I:C1167622
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

Fourier	O
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	B:C1167622
interaction	I:C1167622
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

Fourier	O
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	O
interaction	I:C1167622
among	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

Fourier	O
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	O
interaction	I:C1167622
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	B:C0304463
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

Fourier	O
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	O
interaction	I:C1167622
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	O
and	O
polymer	B:C0063242
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

Fourier	O
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	O
interaction	I:C1167622
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	B:C0024477
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

Fourier	O
transform	I:C0206055
infrared	I:C0206055
indicated	O
a	O
strong	O
molecular	O
interaction	I:C1167622
among	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
.	O

It	O
was	O
evident	O
that	O
alkalizer	B:C0304463
interacts	O
with	O
benzimidazole	O
ring	O
and	O
/	O
or	O
sulfonyl	O
group	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
for	O
enhancing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
stability	O
in	O
gastric	O
fluid	I:C2828094
.	O

It	O
was	O
evident	O
that	O
alkalizer	O
interacts	O
with	O
benzimidazole	O
ring	O
and	O
/	O
or	O
sulfonyl	O
group	O
of	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
for	O
enhancing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
stability	O
in	O
gastric	O
fluid	I:C2828094
.	O

It	O
was	O
evident	O
that	O
alkalizer	O
interacts	O
with	O
benzimidazole	O
ring	O
and	O
/	O
or	O
sulfonyl	O
group	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
for	O
enhancing	O
esomeprazole	B:C3883231
magnesium	I:C3883231
dihydrate	I:C3883231
stability	O
in	O
gastric	O
fluid	I:C2828094
.	O

It	O
was	O
evident	O
that	O
alkalizer	O
interacts	O
with	O
benzimidazole	O
ring	O
and	O
/	O
or	O
sulfonyl	O
group	O
of	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
for	O
enhancing	O
esomeprazole	O
magnesium	I:C3883231
dihydrate	I:C3883231
stability	O
in	O
gastric	B:C2828094
fluid	I:C2828094
.	O

Regarding	O
the	O
in	B:C1515655
vivo	I:C1515655
absorption	O
studies	O
in	O
beagle	O
dogs	I:C0324306
,	O
the	O
optimized	O
SD	O
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	O
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

Regarding	O
the	O
in	O
vivo	I:C1515655
absorption	O
studies	B:C2603343
in	O
beagle	O
dogs	I:C0324306
,	O
the	O
optimized	O
SD	O
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	O
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

Regarding	O
the	O
in	O
vivo	I:C1515655
absorption	O
studies	O
in	O
beagle	B:C0324306
dogs	I:C0324306
,	O
the	O
optimized	O
SD	O
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	O
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

Regarding	O
the	O
in	O
vivo	I:C1515655
absorption	O
studies	O
in	O
beagle	O
dogs	I:C0324306
,	O
the	O
optimized	O
SD	B:C3859614
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	O
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

Regarding	O
the	O
in	O
vivo	I:C1515655
absorption	O
studies	O
in	O
beagle	O
dogs	I:C0324306
,	O
the	O
optimized	O
SD	O
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	B:C0939400
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

The	O
current	O
alkalizer	B:C0304463
-	O
containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	O
drugs	O
without	O
using	O
enteric	O
coating	I:C0039226
method	O
.	O

The	O
current	O
alkalizer	O
-	O
containing	O
SD	B:C3859614
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	O
drugs	O
without	O
using	O
enteric	O
coating	I:C0039226
method	O
.	O

The	O
current	O
alkalizer	O
-	O
containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	B:C0001128
-	O
labile	O
drugs	O
without	O
using	O
enteric	O
coating	I:C0039226
method	O
.	O

The	O
current	O
alkalizer	O
-	O
containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	B:C0443343
drugs	O
without	O
using	O
enteric	O
coating	I:C0039226
method	O
.	O

The	O
current	O
alkalizer	O
-	O
containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	O
drugs	B:C0013227
without	O
using	O
enteric	O
coating	I:C0039226
method	O
.	O

The	O
current	O
alkalizer	O
-	O
containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	O
drugs	O
without	O
using	O
enteric	B:C0039226
coating	I:C0039226
method	O
.	O

